摘要
目的探讨中药厚朴的有效单体成分和厚朴酚对非小细胞肺癌紫杉醇(paclitaxel,PTX)耐药性的逆转作用及可能机制。方法以非小细胞肺癌细胞株A549和PTX耐药细胞株A549T作为研究对象,分为空白对照组、和厚朴酚组、紫杉醇组、和厚朴酚+紫杉醇组,和厚朴酚组、紫杉醇组分别使用一定浓度的药物干预细胞,和厚朴酚+紫杉醇组使用两种药物联合干预细胞,空白对照组不干预。通过MTT实验、流式细胞术、细胞免疫荧光实验及Western Blot免疫印迹实验,观察和厚朴酚对A549T细胞株紫杉醇耐药性的影响。结果和厚朴酚联合紫杉醇干预体外培养的A549T细胞时,细胞存活率较对照组显著降低;和厚朴酚干预体外培养的A549T后,与对照组相比,G2/M期细胞数量增加,细胞P-糖蛋白(P-glycoprotein,P-gp)表达水平降低。结论和厚朴酚能逆转体外培养的A549T细胞的紫杉醇耐药性,其机制与抑制P-gp蛋白的表达,减少药物外排有关。
Objective This study aimed to explore the potential of Honokiol in reversing paclitaxel resistance and to understand its underlying mechanisms in non-small cell lung cancer(NSCLC).Methods Using the non-small cell lung cancer cell line A549 and the paclitaxel-resistant cell line A549T as research subjects,A549T cells were divided into the control group,Honoliol group,Pacli-taxel group and Honokiol+Paclitaxel group.Cells of Honoliol group and Paclitaxel group were treated with a certain concentration of Honoliol or Paclitaxel respectively,while the cells of Honokiol+Paclitaxel group were treated with these two drugs.We assessed the ef-fects of honokiol on Paclitaxel-resistant cell line A549T using various methods including MTT assay,flow cytometry,cell immunofluo-rescence assay and Western blot analysis.Results When honokiol was combined with paclitaxel to intervene with A549T cells cultured in vitro,the cell survival rate was significantly reduced compared to the control group;after honokiol intervention with A549T cells cul-tured in vitro,the number of cells in the G2/M phase increased,and the expression level of P-glycoprotein(P-gp)was decreased com-pared to the control group.Conclusion Honokiol could reverse the paclitaxel resistance of A549T cells cultured in vitro,and its mecha-nism was related to the inhibition of P-glycoprotein(P-gp)expression levels and the reduction of drug efflux.
作者
戴曦
唐大春
袁竞
余文静
DAI Xi;TANG Dachun;YUAN Jing;YU Wenjing(Department of Respiratory and Critical Care Medicine,The Affiliated Hospital,Southwest Medical University,Luzhou 646000,China;Department of Respiratory Medicine,Luxian People’s Hospital,Luzhou 646000,China;Department of Laboratory Medicine,Luzhou People’s Hospital,Luzhou 646000,China;College of Basic Medicine,Southwest Medical University,Luzhou 646000,China)
出处
《西南医科大学学报》
2024年第4期316-320,共5页
Journal of Southwest Medical University
基金
四川省自然科学基金项目(2022NSFSC0729)
西南医科大学附属医院科研项目(19039,17180)。
关键词
和厚朴酚
非小细胞肺癌
紫杉醇
多药耐药
P-糖蛋白
Honokiol
Non-small lung cancer(NSCLC)
Paclitaxel
Multidrug resistance
P-glycoprotein
